Developer docs
API playgroundTry for free, no card

Search company profiles

ABL Diagnostics

Full company profile

uuid000vyzy

Namestring
ABL Diagnostics
Legal namestring
ABL Diagnostics S.A.
Company typeenum
Public
Founded yearint
2000
Descriptiontext

ABL Diagnostics S.A. is a French publicly traded molecular diagnostics company (Euronext Paris: ABLD) headquartered in Woippy, France, with manufacturing operations in Marseille and Luxembourg. The company develops and commercializes CE-IVD and RUO molecular diagnostic assays, software, and laboratory automation for infectious disease genotyping and drug resistance testing, organized around two proprietary technology brands: DeepChek (genotyping through NGS and Sanger sequencing) and UltraGene (real-time PCR detection and quantification). ABL's product portfolio spans HIV, tuberculosis, SARS-CoV-2, viral hepatitis B and C, HPV, CMV, HSV, BKV, RSV, and Salmonella, supported by companion bioinformatics software (ViroScore, BacterioChek, MicrobioChek, DeepChek Software) and the Nadis CE-marked EMR system used in more than 200 French hospitals for HIV and viral hepatitis patient management. The company holds unique regulatory certifications including the only CE-IVD marked full-genome HIV-1 genotyping assay worldwide, ISO 13485:2016 certification, and a renewed US Patent (8,859,198 B2) for hepatitis B genotyping.

ABL generates revenue through three streams: (1) molecular biology assays and kits sold via one-time licenses through direct sales and exclusive distributors globally; (2) recurring software license subscriptions for DeepChek, ViroScore, and BacterioChek platforms; and (3) clinical services and CRO revenue through its CDL Pharma subsidiary, including a recently signed multi-year neurodegenerative disease contract worth up to €2.7M through 2031. Distribution is hybrid: an in-house sales team and a wholly-owned US subsidiary (AdvancedDx Biological Laboratories USA Inc., operating since 2019) complemented by an exclusive distributor network active on all continents, with strategic supplier agreements with Thermo Fisher Scientific, QIAGEN, Roche, and Illumina securing the supply chain. Reported H1 2025 revenue was €2.85M with DeepChek HIV products growing 73% YoY, and external analyst projections point to approximately €12.2M in 2026 revenue.

Short descriptiontext

ABL Diagnostics is a French public molecular diagnostics company that develops CE-IVD assays, sequencing-based genotyping kits (DeepChek), real-time PCR tests (UltraGene), and clinical software for infectious disease drug resistance testing, serving clinical pathology labs, hospitals, and pharmaceutical companies globally through direct sales and exclusive distributors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWoippy, France
HQ citystring
Woippy
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics kits, infectious disease genotyping, HIV resistance testing, real-time PCR assays, clinical diagnostic software
Industry6 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
NAICS code5 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers513210
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Diagnostics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Molecular Biology Assays and Kits
TypeOne Time License
Description

ABLD generates recurring revenues from molecular biology products including DeepChek genotyping kits (NGS and Sanger-based) and UltraGene real-time PCR assays covering infectious disease applications including HIV, SARS-CoV-2, tuberculosis, viral hepatitis B and C, 16S/18S RNA, and other viral and bacterial targets. Revenue is generated through direct sales and exclusive distributors.

abldiagnostics.com
2Software Licenses and Analytics
TypeSubscription Recurring
Description

DeepChek software, ViroScore-HIV, BacterioChek-TB, and other downstream analysis software platforms are commercialized with annual software licenses. DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025.

businesswire.com
3Clinical Services and CRO
TypeProfessional Services
Description

ABL Diagnostics operates clinical services in partnership with CDL Pharma, generating progressive revenue from multi-year international clinical programs. Services include neurodegenerative disease research, laboratory services, and third-party clinical trial management through the US subsidiary.

businesswire.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Laboratory and research products sold via direct inquiry and distributor network
ModelOtherBilling cadenceMulti-year contract
Notes

Products are commercialized globally through the company's own sales team and exclusive distributors. Pricing appears to be quote-based and negotiated directly with academic clinical pathology labs, private reference labs, and research institutions. No public pricing list is available on the company website.

abldiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 10 records shown
1DeepChek
Description

Genotyping through NGS and Sanger sequencing technology for HIV, SARS-CoV-2, HCV, TB, and other pathogens

abldiagnostics.com
+9 more records
Core offering1 text field

ABL Diagnostics develops, manufactures, and commercializes molecular diagnostic kits and supporting software for infectious disease genotyping. Its portfolio centers on two proprietary platforms: DeepChek (genotyping through next-generation sequencing and Sanger sequencing) and UltraGene (real-time PCR molecular detection). The company also offers companion analysis software (ViroScore, DeepChek Software, MicrobioChek, BacterioChek, SeqHepB), the Nadis electronic medical record system, specimen collection kits, and laboratory automation robots.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025
+2 more records
Product overview1 text field

ABL Diagnostics offers a comprehensive molecular diagnostics portfolio organized around two core technology brands: DeepChek for genotyping through next-generation sequencing (NGS) and Sanger sequencing, and UltraGene for real-time PCR detection and quantification. The DeepChek platform provides assays for HIV (whole genome, integrase, protease/reverse transcriptase), tuberculosis, SARS-CoV-2, HCV, HBV, and other pathogens, supported by companion software including DeepChek Software, ViroScore, MicrobioChek, and BacterioChek. The UltraGene brand covers syndromic qPCR panels for respiratory, gastrointestinal, STI, hepatitis, and other infections. Digital solutions include Nadis electronic medical records (CE-marked, used in 200+ French hospitals) and SeqHepB for hepatitis B analysis. The company also provides specimen collection kits (MediaChek), liquid handling automation (DeepChek and OpenChek pipetting robots), and supports multiple NGS platforms including Illumina iSeq/MiSeq, Element Biosciences AVITI, MGI DNBSEQ, and VELA Sentosa through its platform-agnostic approach.

Product and service2 records
1DeepChek Whole Genome HIV-1 Genotyping Assay
CategoryMolecular Diagnostics Kit
Description

CE-IVD marked whole-genome HIV-1 genotyping assay that enables comprehensive resistance profiling across all HIV-1 genomic regions. Validated for use in routine diagnostic laboratories.

2DeepChek Protease/Reverse Transcriptase Genotyping Assay
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-12
Description

ABL Diagnostics and CDL Pharma secured a multi-year international contract with a European pharmaceutical company for neurodegenerative disease research services involving 30 centers across 11 countries. Services are operated by CDL Pharma and distributed by ABL Diagnostics, with total potential value of approximately €2.7 million through 2031, with initial payment exceeding €100,000. The partnership generates progressive revenue based on clinical program performance and enhances visibility of future revenues.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-09
Description

ABL Diagnostics advanced its platform-agnostic NGS strategy by verifying DeepChek assays on Element Biosciences' AVITI sequencer, expanding the range of compatible NGS platforms for ABLD's infectious disease genotyping solutions.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-11
Description

ABL Diagnostics reinforced strategic supplier agreements with multiple leading life science and molecular biology companies including Thermo Fisher Scientific, QIAGEN, Roche, Illumina, and others to secure a robust supply chain supporting commercial growth. The renewed agreements provide improved commercial conditions including more competitive pricing, optimized contractual terms, and enhanced supply security, strengthening the company's cost structure and improving margin expectations for 2026.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-11-24
Description

ABL Diagnostics announced a partnership with seqWell to develop a new library preparation solution for next-generation sequencing (NGS) of infectious diseases. The new product, integrated into ABL's DeepChek platform, aims to reduce hands-on time, improve performance, and support high-volume microbiology labs, particularly for HIV and tuberculosis genotyping.

5ELTA 90 Medical Science
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-20
Description

ABL Diagnostics and ELTA 90 Medical Science won a tender to deliver a whole genome HIV genotyping solution in Montenegro, marking a significant upgrade in the country's HIV drug resistance testing capabilities. The project combines ABL's HIV assays and bioinformatics software with ELTA 90's Illumina-based NGS systems to create a scalable, high-precision platform supporting Montenegro's move to adopt state-of-the-art HIV surveillance.

einpresswire.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-14
Description

ABL Diagnostics signed an exclusive distribution agreement with Eurobio Scientific for its VELA product line in the French public hospital market. The partnership aims to improve access to advanced molecular diagnostics and enhance customer service, leveraging Eurobio Scientific's existing distribution channels in France.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

ABL Diagnostics and VELA Diagnostics expanded their strategic partnership involving the transition of reagent supply to ABL Diagnostics for the EMEA region and integration of VELA Europe's team into ABL Diagnostics. They also validated automation of DeepChek assays on the Sentosa platform, enhancing infectious disease genotyping capabilities across the EMEA region.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2025-10-30
Description

ABL Diagnostics expanded its collaboration with Université Grenoble Alpes and CHU Grenoble Alpes to develop and provide HCV genotyping and resistance testing solutions based on NGS technology. The partnership offers a validated portfolio of DeepChek HCV assays and bioinformatics software for research applications, aiming to enhance understanding of viral diversity and drug resistance while aligning with ABL Diagnostics' broader goal of advancing viral hepatitis molecular diagnostics.

9Riken Genesis (Japan)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

ABL Diagnostics signed an exclusive distribution agreement with Riken Genesis Co., Ltd. for its DeepChek and UltraGene molecular assays across laboratories in Japan, strengthening ABLD's diagnostics portfolio in the Asia-Pacific region.

abldiagnostics.com
10MGI Tech
Strategic tierStrategicTypeTechnology or Integration
Description

MGI and ABL Diagnostics announced a partnership showcased at ESCMID Global 2024, integrating ABLD's DeepChek technology with MGI's DNBSEQ-E25 sequencer for the European and African market, providing microbiology labs with an end-to-end NGS solution.

abldiagnostics.com
Strategic tierRegionalTypeGTM or Marketing Partner
Description

AdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics, executed a co-marketing agreement with Complete Genomics LLC to co-promote Next Generation Sequencing microbiology solutions in the USA market.

12Medline Industries LP (USA)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

AdvancedDx Biological Laboratories USA Inc. executed a non-exclusive distribution agreement with Medline Industries LP to promote and commercialize ABLD's NGS Prep Kits in the United States, expanding reach in the US distribution channel.

abldiagnostics.com
Strategic tierStrategicTypeImplementation/ SI/ Consulting Partner
Description

AdvancedDx Biological Laboratories USA Inc. expanded its logistics and storage capacity through a new agreement with VELA Diagnostics USA Inc. for supporting and managing third-parties' clinical trials in the USA.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

ABL Diagnostics strengthened its historic partnership with Roche Diagnostics Spain to extend its offering to the Spanish market, reinforcing its position as a leader in HIV genotyping in Spain.

Strategic tierCoreTypeTechnology or Integration
Description

ABL Diagnostics signed a Channel Partners Agreement with Illumina to offer combined DeepChek products on the iSeq 100 and MiSeq next-generation sequencing platforms to microbiology laboratories in mainland France, Belgium, and Luxembourg.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

French-headquartered microbiology and molecular diagnostics leader with the BIOFIRE FilmArray syndromic panels and VITEK MS identification systems. Comparable as a microbiology-focused incumbent with overlapping infectious disease menu and overlapping hospital-customer footprint in Europe.

TypeBroad incumbent
Description

Italian diagnostics company with a growing molecular infectious disease portfolio (LIAISON MDX platform) including respiratory and STI panels. Comparable as a European-headquartered mid-cap competitor expanding automated molecular offerings adjacent to ABL's infectious disease focus.

TypeBroad incumbent
Description

Markets the Panther and Panther Fusion fully automated molecular diagnostic systems used for sexually transmitted infections, HPV, and viral load testing. Comparable as a broad incumbent with overlapping infectious disease menu and significant commercial reach in women's health and hospital labs.

TypeDirect peer
Description

Korea-based molecular diagnostics company specializing in multiplex syndromic PCR assays for infectious diseases (respiratory, STI, gastrointestinal). Directly comparable to ABL's UltraGene real-time PCR assays in syndromic infectious disease menu and similar hospital/reference lab target customers.

5Abbott Molecular
TypeBroad incumbent
Description

Operates the m2000 and Alinity m automated molecular diagnostic systems serving HIV, HCV, HBV, and CT/NG testing. Comparable as a large incumbent in infectious disease molecular diagnostics competing for the same hospital and reference-lab customers as ABL's DeepChek assays.

TypeBroad incumbent
Description

Global molecular diagnostics and life science tools leader with HIV/HCV viral load assays (artus, QIAsymphony) and a broad sample-prep franchise. Comparable to ABL Diagnostics as both an incumbent in molecular infectious disease testing and a strategic supplier (reagent partnership) to ABL.

TypeBroad incumbent
Description

Major life science tools and clinical diagnostics company with the QX200 Droplet Digital PCR system and a broad molecular biology reagent portfolio. Comparable as a broad incumbent in molecular biology tools and as a supplier/distribution peer in the same research and clinical workflows as ABL.

TypeBroad incumbent
Description

Acquired Hain Lifescience, maker of the Fluorotype and GenoType line probe assays for TB drug resistance detection. Comparable as a TB drug resistance testing peer offering molecular alternatives to ABL's DeepChek 13-Plex KB assay and upcoming whole-genome TB NGS solution.

TypeBroad incumbent
Description

Owns the cobas automated molecular platform widely used for HIV and HCV viral load testing in hospitals and reference labs. Comparable as the dominant incumbent ABL competes against in HIV diagnostics; also a strategic supplier to ABL.

TypeBroad incumbent
Description

GeneXpert system is the de facto standard for rapid MTB/RIF tuberculosis drug resistance detection worldwide. Directly comparable to ABL's DeepChek TB 13-Plex KB assay and whole-genome TB NGS solution as the dominant automated TB resistance testing platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration10 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ABL Diagnostics

Molecular Diagnosticsabldiagnostics.com

ABL Diagnostics is a French public molecular diagnostics company that develops CE-IVD assays, sequencing-based genotyping kits (DeepChek), real-time PCR tests (UltraGene), and clinical software for infectious disease drug resistance testing, serving clinical pathology labs, hospitals, and pharmaceutical companies globally through direct sales and exclusive distributors.

What ABL Diagnostics does

ABL Diagnostics S.A. is a French publicly traded molecular diagnostics company (Euronext Paris: ABLD) headquartered in Woippy, France, with manufacturing operations in Marseille and Luxembourg. The company develops and commercializes CE-IVD and RUO molecular diagnostic assays, software, and laboratory automation for infectious disease genotyping and drug resistance testing, organized around two proprietary technology brands: DeepChek (genotyping through NGS and Sanger sequencing) and UltraGene (real-time PCR detection and quantification). ABL's product portfolio spans HIV, tuberculosis, SARS-CoV-2, viral hepatitis B and C, HPV, CMV, HSV, BKV, RSV, and Salmonella, supported by companion bioinformatics software (ViroScore, BacterioChek, MicrobioChek, DeepChek Software) and the Nadis CE-marked EMR system used in more than 200 French hospitals for HIV and viral hepatitis patient management. The company holds unique regulatory certifications including the only CE-IVD marked full-genome HIV-1 genotyping assay worldwide, ISO 13485:2016 certification, and a renewed US Patent (8,859,198 B2) for hepatitis B genotyping.

ABL generates revenue through three streams: (1) molecular biology assays and kits sold via one-time licenses through direct sales and exclusive distributors globally; (2) recurring software license subscriptions for DeepChek, ViroScore, and BacterioChek platforms; and (3) clinical services and CRO revenue through its CDL Pharma subsidiary, including a recently signed multi-year neurodegenerative disease contract worth up to €2.7M through 2031. Distribution is hybrid: an in-house sales team and a wholly-owned US subsidiary (AdvancedDx Biological Laboratories USA Inc., operating since 2019) complemented by an exclusive distributor network active on all continents, with strategic supplier agreements with Thermo Fisher Scientific, QIAGEN, Roche, and Illumina securing the supply chain. Reported H1 2025 revenue was €2.85M with DeepChek HIV products growing 73% YoY, and external analyst projections point to approximately €12.2M in 2026 revenue.

ABL Diagnostics firmographics

Firmographics
Name
ABL Diagnostics
Legal name
ABL Diagnostics S.A.
Website
https://abldiagnostics.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Short description
ABL Diagnostics is a French public molecular diagnostics company that develops CE-IVD assays, sequencing-based genotyping kits (DeepChek), real-time PCR tests (UltraGene), and clinical software for infectious disease drug resistance testing, serving clinical pathology labs, hospitals, and pharmaceutical companies globally through direct sales and exclusive distributors.
Ownership category
akta.pro rank

ABL Diagnostics industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)

Keywords

  • Molecular diagnostics kits
  • Infectious disease genotyping
  • HIV resistance testing
  • Real-time PCR assays
  • Clinical diagnostic software

Where ABL Diagnostics is headquartered

Location

Headquarters

HQ city
Woippy
HQ country
France
HQ region
Europe

Offices5 records

Markets served

ABL Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Molecular Biology Assays and Kits: ABLD generates recurring revenues from molecular biology products including DeepChek genotyping kits (NGS and Sanger-based) and UltraGene real-time PCR assays covering infectious disease applications including HIV, SARS-CoV-2, tuberculosis, viral hepatitis B and C, 16S/18S RNA, and other viral and bacterial targets. Revenue is generated through direct sales and exclusive distributors.
  2. Software Licenses and Analytics: DeepChek software, ViroScore-HIV, BacterioChek-TB, and other downstream analysis software platforms are commercialized with annual software licenses. DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025.
  3. Clinical Services and CRO: ABL Diagnostics operates clinical services in partnership with CDL Pharma, generating progressive revenue from multi-year international clinical programs. Services include neurodegenerative disease research, laboratory services, and third-party clinical trial management through the US subsidiary.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractLaboratory and research products sold via direct inquiry and distributor network

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

ABL Diagnostics product offering

Product offering

Core offering

ABL Diagnostics develops, manufactures, and commercializes molecular diagnostic kits and supporting software for infectious disease genotyping. Its portfolio centers on two proprietary platforms: DeepChek (genotyping through next-generation sequencing and Sanger sequencing) and UltraGene (real-time PCR molecular detection). The company also offers companion analysis software (ViroScore, DeepChek Software, MicrobioChek, BacterioChek, SeqHepB), the Nadis electronic medical record system, specimen collection kits, and laboratory automation robots.

Product overview

ABL Diagnostics offers a comprehensive molecular diagnostics portfolio organized around two core technology brands: DeepChek for genotyping through next-generation sequencing (NGS) and Sanger sequencing, and UltraGene for real-time PCR detection and quantification. The DeepChek platform provides assays for HIV (whole genome, integrase, protease/reverse transcriptase), tuberculosis, SARS-CoV-2, HCV, HBV, and other pathogens, supported by companion software including DeepChek Software, ViroScore, MicrobioChek, and BacterioChek. The UltraGene brand covers syndromic qPCR panels for respiratory, gastrointestinal, STI, hepatitis, and other infections. Digital solutions include Nadis electronic medical records (CE-marked, used in 200+ French hospitals) and SeqHepB for hepatitis B analysis. The company also provides specimen collection kits (MediaChek), liquid handling automation (DeepChek and OpenChek pipetting robots), and supports multiple NGS platforms including Illumina iSeq/MiSeq, Element Biosciences AVITI, MGI DNBSEQ, and VELA Sentosa through its platform-agnostic approach.

Differentiator

Problem solved

Functional benefit

Brands

  • DeepChek: Genotyping through NGS and Sanger sequencing technology for HIV, SARS-CoV-2, HCV, TB, and other pathogens
  • UltraGene
  • MediaChek
  • Nadis
  • ViroScore
  • BacterioChek
  • MicrobioChek
  • CRISPRChek
  • HybridChek
  • SeqHepB

Products and services

  • DeepChek Whole Genome HIV-1 Genotyping Assay CE-IVD marked whole-genome HIV-1 genotyping assay that enables comprehensive resistance profiling across all HIV-1 genomic regions. Validated for use in routine diagnostic laboratories.
  • DeepChek Protease/Reverse Transcriptase Genotyping Assay

Quantifiable outcome

  • DeepChek HIV products grew 73% year-on-year to €1.20 million in H1 2025
  • +2 more outcomes

Companies that use ABL Diagnostics

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles5 records

ABL Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability8 records

Feature7 records

ABL Diagnostics partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, strategic and regional.

  • CDL PharmacoreStrategic or Co-development Partner · 12 June 2026ABL Diagnostics and CDL Pharma secured a multi-year international contract with a European pharmaceutical company for neurodegenerative disease research services involving 30 centers across 11 countries. Services are operated by CDL Pharma and distributed by ABL Diagnostics, with total potential value of approximately €2.7 million through 2031, with initial payment exceeding €100,000. The partnership generates progressive revenue based on clinical program performance and enhances visibility of future revenues.
  • Element BiosciencesstrategicTechnology or Integration · 9 June 2026ABL Diagnostics advanced its platform-agnostic NGS strategy by verifying DeepChek assays on Element Biosciences' AVITI sequencer, expanding the range of compatible NGS platforms for ABLD's infectious disease genotyping solutions.
  • Thermo Fisher Scientific, QIAGEN, Roche, IlluminacoreTechnology or Integration · 11 February 2026ABL Diagnostics reinforced strategic supplier agreements with multiple leading life science and molecular biology companies including Thermo Fisher Scientific, QIAGEN, Roche, Illumina, and others to secure a robust supply chain supporting commercial growth. The renewed agreements provide improved commercial conditions including more competitive pricing, optimized contractual terms, and enhanced supply security, strengthening the company's cost structure and improving margin expectations for 2026.
  • seqWellstrategicTechnology or Integration · 24 November 2025ABL Diagnostics announced a partnership with seqWell to develop a new library preparation solution for next-generation sequencing (NGS) of infectious diseases. The new product, integrated into ABL's DeepChek platform, aims to reduce hands-on time, improve performance, and support high-volume microbiology labs, particularly for HIV and tuberculosis genotyping.
  • ELTA 90 Medical ScienceregionalChannel Partner/ Reseller/ Distributor · 20 November 2025ABL Diagnostics and ELTA 90 Medical Science won a tender to deliver a whole genome HIV genotyping solution in Montenegro, marking a significant upgrade in the country's HIV drug resistance testing capabilities. The project combines ABL's HIV assays and bioinformatics software with ELTA 90's Illumina-based NGS systems to create a scalable, high-precision platform supporting Montenegro's move to adopt state-of-the-art HIV surveillance.
  • Eurobio Scientific (France)regionalChannel Partner/ Reseller/ Distributor · 14 November 2025ABL Diagnostics signed an exclusive distribution agreement with Eurobio Scientific for its VELA product line in the French public hospital market. The partnership aims to improve access to advanced molecular diagnostics and enhance customer service, leveraging Eurobio Scientific's existing distribution channels in France.
  • VELA DiagnosticscoreStrategic or Co-development Partner · 4 November 2025ABL Diagnostics and VELA Diagnostics expanded their strategic partnership involving the transition of reagent supply to ABL Diagnostics for the EMEA region and integration of VELA Europe's team into ABL Diagnostics. They also validated automation of DeepChek assays on the Sentosa platform, enhancing infectious disease genotyping capabilities across the EMEA region.
  • Université Grenoble Alpes and CHU Grenoble AlpesstrategicStrategic or Co-development Partner · 30 October 2025ABL Diagnostics expanded its collaboration with Université Grenoble Alpes and CHU Grenoble Alpes to develop and provide HCV genotyping and resistance testing solutions based on NGS technology. The partnership offers a validated portfolio of DeepChek HCV assays and bioinformatics software for research applications, aiming to enhance understanding of viral diversity and drug resistance while aligning with ABL Diagnostics' broader goal of advancing viral hepatitis molecular diagnostics.
  • Riken Genesis (Japan)regionalChannel Partner/ Reseller/ DistributorABL Diagnostics signed an exclusive distribution agreement with Riken Genesis Co., Ltd. for its DeepChek and UltraGene molecular assays across laboratories in Japan, strengthening ABLD's diagnostics portfolio in the Asia-Pacific region.
  • MGI TechstrategicTechnology or IntegrationMGI and ABL Diagnostics announced a partnership showcased at ESCMID Global 2024, integrating ABLD's DeepChek technology with MGI's DNBSEQ-E25 sequencer for the European and African market, providing microbiology labs with an end-to-end NGS solution.
  • Complete Genomics LLC (USA)regionalGTM or Marketing PartnerAdvancedDx Biological Laboratories USA Inc., an affiliate of ABL Diagnostics, executed a co-marketing agreement with Complete Genomics LLC to co-promote Next Generation Sequencing microbiology solutions in the USA market.
  • Medline Industries LP (USA)regionalChannel Partner/ Reseller/ DistributorAdvancedDx Biological Laboratories USA Inc. executed a non-exclusive distribution agreement with Medline Industries LP to promote and commercialize ABLD's NGS Prep Kits in the United States, expanding reach in the US distribution channel.
  • VELA Diagnostics USA Inc.strategicImplementation/ SI/ Consulting PartnerAdvancedDx Biological Laboratories USA Inc. expanded its logistics and storage capacity through a new agreement with VELA Diagnostics USA Inc. for supporting and managing third-parties' clinical trials in the USA.
  • Roche Diagnostics SpainregionalChannel Partner/ Reseller/ DistributorABL Diagnostics strengthened its historic partnership with Roche Diagnostics Spain to extend its offering to the Spanish market, reinforcing its position as a leader in HIV genotyping in Spain.
  • IlluminacoreTechnology or IntegrationABL Diagnostics signed a Channel Partners Agreement with Illumina to offer combined DeepChek products on the iSeq 100 and MiSeq next-generation sequencing platforms to microbiology laboratories in mainland France, Belgium, and Luxembourg.

Scale indicators10 records

Recent moves9 records

Expansion highlights8 records

ABL Diagnostics competitors and assessment

Company assessment

Broad incumbents

  • bioMérieux: French-headquartered microbiology and molecular diagnostics leader with the BIOFIRE FilmArray syndromic panels and VITEK MS identification systems. Comparable as a microbiology-focused incumbent with overlapping infectious disease menu and overlapping hospital-customer footprint in Europe.
  • DiaSorin: Italian diagnostics company with a growing molecular infectious disease portfolio (LIAISON MDX platform) including respiratory and STI panels. Comparable as a European-headquartered mid-cap competitor expanding automated molecular offerings adjacent to ABL's infectious disease focus.
  • Hologic: Markets the Panther and Panther Fusion fully automated molecular diagnostic systems used for sexually transmitted infections, HPV, and viral load testing. Comparable as a broad incumbent with overlapping infectious disease menu and significant commercial reach in women's health and hospital labs.
  • Abbott Molecular: Operates the m2000 and Alinity m automated molecular diagnostic systems serving HIV, HCV, HBV, and CT/NG testing. Comparable as a large incumbent in infectious disease molecular diagnostics competing for the same hospital and reference-lab customers as ABL's DeepChek assays.
  • QIAGEN: Global molecular diagnostics and life science tools leader with HIV/HCV viral load assays (artus, QIAsymphony) and a broad sample-prep franchise. Comparable to ABL Diagnostics as both an incumbent in molecular infectious disease testing and a strategic supplier (reagent partnership) to ABL.
  • Bio-Rad Laboratories: Major life science tools and clinical diagnostics company with the QX200 Droplet Digital PCR system and a broad molecular biology reagent portfolio. Comparable as a broad incumbent in molecular biology tools and as a supplier/distribution peer in the same research and clinical workflows as ABL.
  • Bruker (Hain Lifescience): Acquired Hain Lifescience, maker of the Fluorotype and GenoType line probe assays for TB drug resistance detection. Comparable as a TB drug resistance testing peer offering molecular alternatives to ABL's DeepChek 13-Plex KB assay and upcoming whole-genome TB NGS solution.
  • Roche Diagnostics: Owns the cobas automated molecular platform widely used for HIV and HCV viral load testing in hospitals and reference labs. Comparable as the dominant incumbent ABL competes against in HIV diagnostics; also a strategic supplier to ABL.
  • Cepheid (Danaher): GeneXpert system is the de facto standard for rapid MTB/RIF tuberculosis drug resistance detection worldwide. Directly comparable to ABL's DeepChek TB 13-Plex KB assay and whole-genome TB NGS solution as the dominant automated TB resistance testing platform.

Direct peers

  • Seegene: Korea-based molecular diagnostics company specializing in multiplex syndromic PCR assays for infectious diseases (respiratory, STI, gastrointestinal). Directly comparable to ABL's UltraGene real-time PCR assays in syndromic infectious disease menu and similar hospital/reference lab target customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ABL Diagnostics social profiles

Digital presence

ABL Diagnostics compliance and trust

Trust signal

Compliance4 records

ABL Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ABL Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

ABL Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

ABL Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ABL Diagnostics M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ABL Diagnostics

What does ABL Diagnostics do?

ABL Diagnostics develops, manufactures, and commercializes molecular diagnostic kits and supporting software for infectious disease genotyping. Its portfolio centers on two proprietary platforms: DeepChek (genotyping through next-generation sequencing and Sanger sequencing) and UltraGene (real-time PCR molecular detection). The company also offers companion analysis software (ViroScore, DeepChek Software, MicrobioChek, BacterioChek, SeqHepB), the Nadis electronic medical record system, specimen collection kits, and laboratory automation robots.

Is ABL Diagnostics a public or private company?

ABL Diagnostics is a public company. It is classified as public and is currently operating.

When was ABL Diagnostics founded?

ABL Diagnostics was founded in 2000. It employs 11 to 50 people.

Where is ABL Diagnostics based?

ABL Diagnostics is headquartered in Woippy, France, in the Europe region.

How does ABL Diagnostics make money?

Three revenue lines are on record. Molecular Biology Assays and Kits are the primary driver. The others are software Licenses and Analytics and clinical Services and CRO.

Who are ABL Diagnostics's main competitors?

Broad incumbents on record are bioMérieux, DiaSorin, Hologic, Abbott Molecular, QIAGEN, Bio-Rad Laboratories, Bruker (Hain Lifescience), Roche Diagnostics and Cepheid (Danaher). Seegene is listed as a direct peer.

Does ABL Diagnostics have an API?

No public API is recorded for ABL Diagnostics.

What industry is ABL Diagnostics in?

ABL Diagnostics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of IntentABL Texcell Diagnostics terminated the Letter of Intent for acquiring Vela Diagnostics' Singapore and US operations, announced September 21, 2026. The deal, covering 100% of Vela Operations Singapore and Vela Diagnostics USA, will not proceed. The company continues its development strategy across molecular diagnostics and clinical genomics.The future of tradingProsecutor's Appeal Suspends ABL Texcell Diagnostics' IntegraGen AcquisitionA public prosecutor appealed the Évry-Courcouronnes Commercial Court's October 9, 2026 judgment authorizing ABL Texcell Diagnostics' acquisition of IntegraGen's assets and operations. The appeal suspends the judgment, returning IntegraGen to judicial reorganization pending a Paris Court of Appeal decision.The future of tradingProsecutor's Appeal Suspends ABL Diagnostics' Acquisition of IntegraGen AssetsABL Diagnostics' acquisition of IntegraGen's assets and operations is suspended after a public prosecutor's appeal in Évry-Courcouronnes. The appeal challenges the October 9, 2026, ruling selecting the takeover offer, leaving IntegraGen in judicial reorganization pending a Paris Court of Appeal decision.Business Wire BlogABL Texcell Diagnostics: Notice of Appeal by the Public Prosecutor Regarding the IntegraGen Transfer JudgmentThe Public Prosecutor filed an appeal with the Évry-Courcouronnes Judicial Court against the commercial court's October 9, 2026 judgment approving ABL Texcell Diagnostics' acquisition of IntegraGen's assets and business activities. The appeal has suspensive effect, placing IntegraGen back under judicial reorganization proceedings pending the Paris Court of Appeal's decision.Business Wire BlogABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and OperationsABL Texcell Diagnostics acquired IntegraGen's assets and operations, approved by the Evry Commercial Court on October 9, 2026. The acquisition price is €100,000, with an overall economic commitment exceeding €1.27 million, including €150,000 in initial investments. The deal expands the company's expertise into precision oncology, human genetics, and rare diseases.YahooABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and OperationsABL Texcell Diagnostics acquired IntegraGen's assets and operations, approved by the Evry Commercial Court on October 9, 2026. The acquisition price is €100,000, with an overall economic commitment exceeding €1.27 million, including €150,000 in initial investments. The deal marks ABL Texcell's entry into precision oncology and human genetics.Business Wire BlogABL Texcell Diagnostics Strengthens the Foundations of a Stable Shareholder Base and Pursues Its Growth StrategyABL Luxembourg, principal shareholder of ABL Texcell Diagnostics, said it will prioritize long-term investors in any future share disposals, requiring a minimum 12-month lock-up. A final tranche of 10,000 shares on loan to Alumni Capital is expected to be returned by end of October 2026, ending the loan arrangement.Business Wire BlogABL Texcell Diagnostics Raises Its 2026 Revenue Guidance to €13.5 Million - €14.0 MillionABL Texcell Diagnostics raised its 2026 revenue guidance to €13.5-14.0 million, up 10.1-14.1% from the initial target. The guidance reflects first-half revenue of €5.415 million and the expected contribution from the TEXCELL acquisition. The company plans to continue integrating TEXCELL's activities.Business Wire BlogABL Texcell Diagnostics: Availability of the 2026 Half-Year Financial ReportABL Texcell Diagnostics filed its half-year financial report for the period ended 30 June 2026 with the French Financial Markets Authority (AMF) and made it available on its website. The Board approved the interim statements on 8 September 2026, and the statutory auditor's report found no material misstatements.Ideal InvestisseurABL Diagnostics targets acquisition of two Vela group entities in Asia and the United StatesABL Diagnostics signed a non-binding letter of intent to acquire 100% of Vela Operations Singapore and Vela Diagnostics USA. The deal would extend its commercial presence to Asia-Pacific and the United States, with no change in control. Completion is subject to due diligence, final agreements, and regulatory approvals.